Table 3.

The Effect of Lipid Type and Concentration on the Physicochemical Properties of Plain-SLN on 0 and 30 Days

Duration	0 Day			30 Days
Characterization	PS	PDI	ZP	PS	PDI	ZP
Plain-SLN1	303.9 ±10.5	0.273 ± 0.013	−20.1 ± 0.68	321.8 ± 5.5	0.299 ± 0.017	−13.1 ± 1.1
Plain-SLN2	247.6 ± 6.7	0.245 ± 0.012	−17.7 ± 0.84	258.2 ± 6.0	0.302 ± 0.012	−19.9 ± 3.9
Plain-SLN3	219.8 ± 1.9	0.068 ± 0.022	−14.0 ± 0.11	274.8 ± 4.5	0.094 ± 0.023	−20.4 ± 0.58
Plain-SLN4	239.5 ± 6.3	0.092 ± 0.011	−18.0 ± 0.15	266.3 ± 2.0	0.092 ± 0.013	−21.0 ± 0.91
Plain-SLN5	251.5 ± 2.6	0.139 ± 0.052	−21.6 + 0.55	278.3 ± 5.1	0.098 ± 0.017	−21.6 ± 1.73
Plain-SLN6	264.9 ± 7.2	0.171 ± 0.015	−18.8 ± 0.83	292.6 ± 2.4	0.135 ± 0.025	−21.7 ± 0.66

Note: Data were expressed as the mean ± SD, N = 3.

Abbreviations: Plain-SLN, drug free-solid lipid nanoparticle; PS, particle size; PDI, polydispersity index; ZP, zeta potential.